AI-Powered registry to track new prostate cancer drug in real life

NCT ID NCT07484269

Not yet recruiting Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will observe how the drug lutetium-177 vipivotide tetraxetan is actually used in patients with metastatic prostate cancer. Researchers will collect data from medical records across multiple countries, using AI to analyze treatment patterns and outcomes. The goal is to understand real-world usage, not to test the drug's effectiveness directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lutetium (177Lu) vipivotide tetraxetan
What this could lead to: If successful, this registry could provide real-world evidence on how well this treatment works and is used in everyday practice, potentially guiding better care for metastatic prostate cancer.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.